Development of target-specific treatments in multiple myeloma

Asher A. Chanan-Khan, Ivan M Borrello, Kelvin P. Lee, Donna E. Reece

Research output: Contribution to journalArticle

Abstract

In the last decade, the novel agents lenalidomide, bortezomib, and thalidomide have dramatically improved outcomes for patients with multiple myeloma (MM). A number of new therapies with precise targets involved in MM cell growth and replication are now in development and have the potential for further improvements. Second-generation proteasome inhibitors and thalidomide derivatives may offer increased efficacy and safety. Investigational therapies with rationally selected targets in MM include inhibitors of histone deacetylase, heat shock protein 90, mammalian target of rapamycin, BCL2, Akt, mitogen-activated protein kinase, and telomerase. In addition, monoclonal antibodies directed against several targets have been developed and many are showing promise in initial clinical trials in MM. Interest in the ancient remedy of arsenic trioxide has been revived because of its proapoptotic effects on mitochondria, despite its established toxicities. In general, combination regimens are proving the most efficacious, which is to be expected given the multiple overlapping pathways responsible for MM growth and progression.

Original languageEnglish (US)
Pages (from-to)3-15
Number of pages13
JournalBritish Journal of Haematology
Volume151
Issue number1
DOIs
StatePublished - Oct 2010

Fingerprint

Multiple Myeloma
Thalidomide
HSP90 Heat-Shock Proteins
Therapeutics
Investigational Therapies
Proteasome Inhibitors
Histone Deacetylase Inhibitors
Telomerase
Sirolimus
Growth
Mitogen-Activated Protein Kinases
Mitochondria
Monoclonal Antibodies
Clinical Trials
Safety

Keywords

  • bortezomib
  • lenalidomide
  • multiple myeloma
  • tanespimycin
  • thalidomide

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Development of target-specific treatments in multiple myeloma. / Chanan-Khan, Asher A.; Borrello, Ivan M; Lee, Kelvin P.; Reece, Donna E.

In: British Journal of Haematology, Vol. 151, No. 1, 10.2010, p. 3-15.

Research output: Contribution to journalArticle

Chanan-Khan, Asher A. ; Borrello, Ivan M ; Lee, Kelvin P. ; Reece, Donna E. / Development of target-specific treatments in multiple myeloma. In: British Journal of Haematology. 2010 ; Vol. 151, No. 1. pp. 3-15.
@article{f5395c13f4d54f289f7be1b069fce4b1,
title = "Development of target-specific treatments in multiple myeloma",
abstract = "In the last decade, the novel agents lenalidomide, bortezomib, and thalidomide have dramatically improved outcomes for patients with multiple myeloma (MM). A number of new therapies with precise targets involved in MM cell growth and replication are now in development and have the potential for further improvements. Second-generation proteasome inhibitors and thalidomide derivatives may offer increased efficacy and safety. Investigational therapies with rationally selected targets in MM include inhibitors of histone deacetylase, heat shock protein 90, mammalian target of rapamycin, BCL2, Akt, mitogen-activated protein kinase, and telomerase. In addition, monoclonal antibodies directed against several targets have been developed and many are showing promise in initial clinical trials in MM. Interest in the ancient remedy of arsenic trioxide has been revived because of its proapoptotic effects on mitochondria, despite its established toxicities. In general, combination regimens are proving the most efficacious, which is to be expected given the multiple overlapping pathways responsible for MM growth and progression.",
keywords = "bortezomib, lenalidomide, multiple myeloma, tanespimycin, thalidomide",
author = "Chanan-Khan, {Asher A.} and Borrello, {Ivan M} and Lee, {Kelvin P.} and Reece, {Donna E.}",
year = "2010",
month = "10",
doi = "10.1111/j.1365-2141.2010.08262.x",
language = "English (US)",
volume = "151",
pages = "3--15",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Development of target-specific treatments in multiple myeloma

AU - Chanan-Khan, Asher A.

AU - Borrello, Ivan M

AU - Lee, Kelvin P.

AU - Reece, Donna E.

PY - 2010/10

Y1 - 2010/10

N2 - In the last decade, the novel agents lenalidomide, bortezomib, and thalidomide have dramatically improved outcomes for patients with multiple myeloma (MM). A number of new therapies with precise targets involved in MM cell growth and replication are now in development and have the potential for further improvements. Second-generation proteasome inhibitors and thalidomide derivatives may offer increased efficacy and safety. Investigational therapies with rationally selected targets in MM include inhibitors of histone deacetylase, heat shock protein 90, mammalian target of rapamycin, BCL2, Akt, mitogen-activated protein kinase, and telomerase. In addition, monoclonal antibodies directed against several targets have been developed and many are showing promise in initial clinical trials in MM. Interest in the ancient remedy of arsenic trioxide has been revived because of its proapoptotic effects on mitochondria, despite its established toxicities. In general, combination regimens are proving the most efficacious, which is to be expected given the multiple overlapping pathways responsible for MM growth and progression.

AB - In the last decade, the novel agents lenalidomide, bortezomib, and thalidomide have dramatically improved outcomes for patients with multiple myeloma (MM). A number of new therapies with precise targets involved in MM cell growth and replication are now in development and have the potential for further improvements. Second-generation proteasome inhibitors and thalidomide derivatives may offer increased efficacy and safety. Investigational therapies with rationally selected targets in MM include inhibitors of histone deacetylase, heat shock protein 90, mammalian target of rapamycin, BCL2, Akt, mitogen-activated protein kinase, and telomerase. In addition, monoclonal antibodies directed against several targets have been developed and many are showing promise in initial clinical trials in MM. Interest in the ancient remedy of arsenic trioxide has been revived because of its proapoptotic effects on mitochondria, despite its established toxicities. In general, combination regimens are proving the most efficacious, which is to be expected given the multiple overlapping pathways responsible for MM growth and progression.

KW - bortezomib

KW - lenalidomide

KW - multiple myeloma

KW - tanespimycin

KW - thalidomide

UR - http://www.scopus.com/inward/record.url?scp=77956814361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956814361&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08262.x

DO - 10.1111/j.1365-2141.2010.08262.x

M3 - Article

VL - 151

SP - 3

EP - 15

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -